Drug updated on 9/4/2024
Dosage Form | Injection (subcutaneous; 1.75 mg/0.3 mL) |
Drug Class | Melanocortin receptor agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
Latest News
Summary
- Vyleesi (bremelanotide) is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
- This summary is based on the review of four randomized controlled trial(s). [1-4]
- Bremelanotide significantly increased FSFI-desire scores and reduced distress related to low sexual desire in premenopausal women with HSDD, as demonstrated in the phase 3 RECONNECT studies, with sustained improvements observed during a 52-week open-label extension.
- Statistically significant improvements in sexual desire and distress reduction were consistent across various subgroups, including differences in age, weight, BMI, bioavailable testosterone levels, and irrespective of hormonal contraceptive use and HSDD duration.
- Bremelanotide did not have any direct comparative effectiveness data against other drugs in the studies provided.
- Nausea was the most common adverse event (40.0% in phase 3 studies), with some cases leading to discontinuation.
- Other notable adverse events included flushing (20.3%), headache (11.3%), and injection site reactions (5.4%).
- Serious adverse events were rare, with no deaths reported, and small, transient but statistically significant increases in blood pressure were observed.
- Focal hyperpigmentation occurred in more than one-third of subjects with consecutive daily dosing up to 16 days.
- No new safety signals were observed during the 52-week open-label extension phase, with most treatment-emergent adverse events being mild to moderate in intensity.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vyleesi (bremelanotide) Prescribing Information. | 2021 | Palatin Technologies Inc., Cranbury, NJ |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Safety profile of bremelanotide across the clinical development program. | 3,500Subjects F: null% M: null% | 2022 | Journal of Women’s Health |
Prespecified and integrated subgroup analyses from the RECONNECT Phase 3 studies of bremelanotide. | 1,202Subjects F: 100% M: 0% | 2022 | Journal of Women’s Health |
Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. | 1,267Subjects F: 100% M: 0% | 2019 | Obstetrics & Gynecology |
Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. | 1,247Subjects F: 100% M: 0% | 2019 | Obstetrics & Gynecology |
Sex Distribution:
F:%
M:%
3500Subjects
Year:
2022
Source:Journal of Women’s Health
Document Title
Sex Distribution:
F:100%
M:0%
1202Subjects
Year:
2022
Source:Journal of Women’s Health
Sex Distribution:
F:100%
M:0%
1267Subjects
Year:
2019
Source:Obstetrics & Gynecology
Document Title
Sex Distribution:
F:100%
M:0%
1247Subjects
Year:
2019
Source:Obstetrics & Gynecology